Pluristem Therapeutics to Present at the Second Annual Life Science Conference of The Society of Investment Professionals in Germany
NEW YORK, Jun 10, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Mr. Thomas Klein, Pluristem's EU representative, will present at the conference of the Society of Investment Professionals in Germany, the DVFA, on "The Placenta, from the Miracle of Birth to Therapeutics to All". This is the second annual Life Science Conference for the DVFA and Pluristem will present on Tuesday, June 16, 2009 at the DVFA Center, Frankfurt, Germany.
"The German investment community has expressed a great interest in Pluristem over the last several months, which goes hand in hand with the scientific and clinical collaborations that Pluristem has in Germany," stated Zami Aberman, Chairman, President and CEO of Pluristem. "We look forward to treating our first patient in a Phase-I trial utilizing PLX-PAD, our placental-derived cellular product for the treatment of Peripheral Artery Disease in Germany." |
